When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

Brain metastases from prostate cancer (PC) seem to be more frequent ... However, this problem may be overcome by new active drugs such as cabazitaxel. BMs should be distinguished from other ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

Pfizer's prostate cancer drug candidate 'mevrometostat' clinical ... In South Korea, Hanmi Pharmaceutical is developing next-generation anticancer drugs that simultaneously inhibit EZH1 and ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $17.4 billion, has announced results from its Phase 3 TALAPRO-2 study which show that a combination of ...

Opens in a new tab or window An implantable microdevice safely delivered multiple drugs directly into prostate cancer lesions, enabling assessment of tumor-specific responses. All 14 patients ...

A mid-stage study reveals that transdermal estradiol patches may match traditional androgen deprivation therapy in treating prostate cancer with fewer side effects. This approach boosts bone density ...

The study showed that adding Nubeqa to standard therapy with anti-androgen drugs and chemotherapy ... non-metastatic castration-resistant prostate cancer (CRPC), but expansion into hormone ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

This year's commemoration of World Cancer Day offers a three-year journey to raise awareness about one of the world’s biggest ...